Overview

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects

Status:
Recruiting

Trial end date:
2021-09-07

Target enrollment:

Participant gender:

Summary

This is a randomised, double-blind, three-arm, parallel group, single-dose study to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of SB17 compared to EU sourced Stelara® and US sourced Stelara® in healthy subjects

Phase:

Phase 1

Details

Lead Sponsor:

Samsung Bioepis Co., Ltd.

Treatments:

Ustekinumab